23 results
Objective PrimaryDose escalation phase only: To determine the MTD of HCD122 when administered in combination with bendamustineDose expansion phase only: To assess the safety and tolerability of HCD122 in combination with bendamustine SecondaryDose…
Primary objective:To compare the immunological response to vaccination with HPV16 E6 and E7 synthetic long peptides with concomitant application of imiquimod at the vaccination site with vaccination without the concomitant application of imiquimod.…
Primary objective: * Examine the safety and tolerability, both local and general, of ProCervix Solution (escalating doses) and ProCervix Powder in women infected by HPV 16 and/or 18 with normal cytology from Week 0 to Week 10. Secondary objectives…
Primary Objective: • To study the clinical efficacy of local treatment with monobenzone and imiquimod cream on cutaneous metastases in stage III-IV melanoma patients Secondary Objective• To study the induction of local tumor-specific immunity by MI…
Primary objectives: (1) Evaluation of the efficacy of vaccination against HPV 16, 18, 6 and 11 followed by local applications of imiquimod 5% cream compared to treatment with imiquimod alone for usual type VIN, (2) evaluation of the systemic and…
To investigate the effectiveness of imiquimod 5% cream for the treatment of CIN2-3 lesions, compared to LLETZ treatment and to assess long-term disease recurrence, side effects and quality of life associated with different treatment modalities.
To assess the efficacy, evaluate the safety and immunological effect of topical 5% imiquimod cream for vulvar Paget*s disease and the quality of life during treatment.
Primary objective- To explore the pharmacodynamic effects of topically applied IMQ (in combination with or without TS) - To identify dose-response relationship of topically applied IMQ Secondary objective- To assess safety and tolerability of…
Efficacy ObjectivesThe primary efficacy objective:• To evaluate the efficacy of GDC-0199 and rituximab (GDC-0199+R) compared with bendamustine and rituximab (BR) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) as measured…
Primary objectives• To evaluate complement activation after topical imiquimod challenge• To evaluate complement activation after local UV-B challenge
Determine which treatment is the most effective treatment in terms of lesion reduction, costs and patient satisfaction when comparing topical treatment with photodynamic therapy (PDT), 5% 5-fluorouracil (5-FU) cream, 5% Imiquimod (IMI) cream and…
Primary objectives: Evaluation of the efficacy of imiquimod 5% cream compared to treatment with Large Loop excision of the transformation zone (LLETZ) for recurrent/residual CIN.Secondary objectives: evaluation of the effect of treatments on HPV DNA…
The primary objectives of the Phase Ib portion of the study are as follows:* To assess the safety and tolerability of the combination of polatuzumab vedotin with bendamustine and rituximab (BR) or bendamustine and obinutuzumab (BG) when administered…
The objective of the study is to investigate the feasibility and efficacy of treatment with lenalidomide and rituximab with or without bendamustine in patients with relapsed follicular lymphoma.
Primary objective: To assess the efficacy of low dose rate light fractionated aminolevulinic acid-Photodynamic Therapy (ALA-PDT) for treatment of VLS and HSIL. Clinical and histological response. Secondary objectives: Tolerence of ALA-PDT by…
The primary objective for this study is as follows:* To evaluate clinical benefit in terms of PFS, as assessed by an IRF, for GA101 when used incombination with bendamustine compared with bendamustine alone in patients with indolentNHL refractory to…
This study aims to investigate the treatment efficacy, side-effects and quality of life associated with imiquimod treatment of high-grade CIN lesions in a selected population of patients who prefer imiquimod treatment instead of LLETZ. The study…
Primary Objectives- Determine the MTD of pixantrone, rituximab (only in CD20 positive tumors), etoposide, and bendamustine in *fit' patients with rel aNHL of B- or T-cell phenotype.- Evaluate the ORR and PFS using the combination of pixantrone…
Primary• To evaluate the effect of EDP1815 (same dose using EC1 and EC2 capsules) and EDP2939 (two dose levels using EC2 capsules) on the immune system.Secondary• To evaluate the effect of EDP1815 (same dose using EC1 and EC2 capsules) and EDP2939 (…
Primary* To immunologically characterize imiquimod-induced inflammation after 7-day exposure of healthy skin;* To evaluate local complement activation/depositions after a prolonged topical imiquimod challenge;* To evaluate systemic activation of…